fipco

Also post at ≠ endorse; mostly health science posts

[fipco @fipco]

@Drlipid @nationallipid @society_eas @ASPCardio @FamilyHeartFdn Here today.

[fipco @fipco]

Baricitinib #JAK safety trial presented at #EULAR2026 . https://t.co/Eb0Ula82XM

Additional views here https://t.co/jRnhpor3nC

[David Liew @drdavidliew]

Let's talk RA-BRIDGE/RA-BRANCH (the 'new ORAL Surveillance'):
baricitinib vs TNFi RCTs in RA + 1 VTE RF

Big news was secondary endpoints:
MACE (HR 1.06), malignancy (HR 1.27), not sig

The key: how similar is study population to ORAL Surveillance? 1/4
LB0009 #EULAR2026 @RheumNow

[Journal of Clinical Lipidology @LipidJournal]

#JCLSpotlight: Baseline apoB may drive long-term MACE recurrence in very young ACS survivors, highlighting its potential utility for risk stratification beyond traditional lipid markers.

🔗 https://t.co/mIMLJ4OX2C

[Roger Blumenthal @rblument1]

In Defense of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline https://t.co/P8AWGvexJg led by @DrMichaelShapir @AlexRazavi @RonBlankstein @CiccaroneCenter @hopkinsheart

[Daniel J Drucker @DanielJDrucker]

Impressive TRIUMPH-1 #weightloss data for retatrutide https://t.co/aGDw3JcZmf

[fipco @fipco]

@NutritionMadeS3 @EliasBjornson Comparative imaging data are limited. Many unknowns. Here's a PCSK9i study. If you assume olezarsen effect is 50% greater at 18 months vs 12, median % lowering from baseline ~80% of that with PCSK9i on non-calcified plaque, 62% of PCSK9i on LAPV. https://t.co/VSxuxaoHuo

[fipco @fipco]

More interesting context for ESSENCE imaging study. Also in this study, LAPV change with evolocumab -45% at 18 months. ESSENCE: placebo +2.78%, olezarsen -16.62% at 12 months /1 https://t.co/U0YciAjmRD

[fipco @fipco]

• using apple-apples supplement comparison (with similar #'s on statin), incremental cost/qaly 70% lower than new AHA threshold, i.e. highly cost effective
• uses uber conservative assumptions that understate benefit. /3-fin https://t.co/8blGWOkZrd

[fipco @fipco]

New lipid guidelines are a good step forward from the last ones. In my view, apoB adds value beyond traditional measures, including non-HDL-C and newer LDL equations. Even with newer equations, (by some definitions) over half of Americans have apoB-LDL-C discordance. /1 🧵

[fipco @fipco]

When measures disagree, cardiovascular risk tracks with apoB. Systemic review from last year. 👇

To my eyes, recent JAMA cost effectiveness study impressive.
/2 https://t.co/MrBAg9UA8i

[Vumedi Cardio @Cardio_Vumedi]

LDL lowering in primary prevention. Bigger impact than we thought?

Drs. Kevin Maki, @DineshKalra, and Alan Brown show ~30% MACE reduction per ~39 mg/dL LDL drop even in lower-risk patients.

Is it time to treat earlier?

🎥 Watch on #Vumedi - https://t.co/gE1suyAHHD

#LDL #ASCVD #Prevention #Lipidology #VumediCardio @nationallipid

[Gregg Fonarow MD @gcfmd]

Now available!

Generic dapagliflozin 10 mg

30 day supply, direct cash price

$8.36

@ACCinTouch @HFSA @American_Heart @AAHFN @SJGreene_md @ATSandhu @boback @NMHheartdoc @docsabe @HeartDocSadiya

[fipco @fipco]

@TriglycerideF @UCPH_Research Interesting study. After PROMINENT, one probably needs more than this observational study, despite propensity score matching, to support fenofibrate use with statins in those with non-HDL-C>140mg/dL.

[C. Michael Gibson MD @CMichaelGibson]

The recording from today's Baim Grand Rounds with @ProfKausikRay titled, "Changing the Paradigm of ASCVD Prevention" is now available on the Baim website. You can find it here: https://t.co/npsuK6R7L7

[fipco @fipco]

@sanekachakrava1 Thanks for comment. On concern 2: The HOPE-3 trial likely included many with PCE 10y risk 5-7.5% and many of those would also have PREVENT 10y risk 3-5%. https://t.co/nOtQzDTiCV On point 1, there's uncertainty with non-randomized data. At lower doses, risk seems modest.

[C. Michael Gibson MD @CMichaelGibson]

Oil painting I did of Dr. Eugene Braunwald, my friend & mentor since 1986
http://t.co/pPHlZ4P6hB

[Josh @JoshJwageman]

Excess ApoB back in the spotlight! Discordantly high ApoB---increased ACM and CVM in statin-treated patients @ApoDudz @DrScottMurray @MichaelMindrum @NutritionMadeS3 x

https://t.co/JfUS6zmEXm

[fipco @fipco]

@Hragy @ACCinTouch @escardio @Drlipid 1. As @DrMarthaGulati notes, Rx recommended based on LDL>=190, also 30y risk>10%. 2. There is an issue that traditional risk calculators don't reflect causal drivers of disease (lipids/ blood pressure) to the extent seen in short term RCTs or long term genetic studies.

[fipco @fipco]

@drpablocorral Agree with the sentiment. But science takes time. There are hints of benefit from inflammation targeting. I'm hopeful one of the inflammation based strategies will pan out and become a useful treatment adjunct. https://t.co/MNz5bEakXQ

[fipco @fipco]

Somewhat lukewarm view of colchicine in this editorial. "the CLEAR SYNERGY results have brought considerable clinical equipoise for the prescription of colchicine to reduce ASCVD risk"
https://t.co/aUBwtKBCF6

https://t.co/s4PAwArQ5c

[Matthew Herper @matthewherper]

Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target

https://t.co/ADzYb2Zqal via @statnews

[Daniel J Drucker @DanielJDrucker]

ACHIEVE-4 with Orforglipron H2H vs. Insulin glargine #T2D 2,700 people, 2 years, Cardiovascular safety, reduced risk of all cause mortality and no evidence of liver injury https://t.co/eBdD05btfD